Associated Papers
Well-differentiated systemic mastocytosis: Genetics, mast cell immunophenotypes, and KIT autophosphorylation.
Schornack BJ et al.
The Journal of Allergy and Clinical Immunology, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Pathogenic Mechanisms of Systemic Mastocytosis: Unraveling the Genetic Complexity, Bone Marrow Microenvironment, and Clinical Challenges.
Sotiropoulou CD et al.
European Journal of Haematology, 2025
Novel KIT mutation, D816_N819delinsll, in a patient with systemic mastocytosis: a case report.
Juratli HA et al.
Virchows Archiv : an International Journal of Pathology, 2025
Therapeutic advances of targeting receptor tyrosine kinases in cancer.
Tomuleasa C et al.
Signal Transduction and Targeted Therapy, 2024
Prevalence and impact of the KIT M541L variant in patients with mastocytosis.
Aldama LND et al.
Oncotarget, 2024
Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in KIT D816V-Negative Advanced Systemic Mastocytosis.
Naumann N et al.
Cancers, 2024
KIT V560D-Mutated Systemic Mastocytosis Associated With High-Risk Myelodysplastic Syndrome: A Unique Case of Systemic Mastocytosis-Associated Hematologic Neoplasm.
Medawar G et al.
Case Reports in Hematology, 2024
Mastocytosis and related entities: a practical roadmap.
Beyens M et al.
Acta Clinica Belgica, 2023
Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management.
Pardanani A
American Journal of Hematology, 2023
Recalcitrant Cutaneous Mastocytosis Treated With Genetically Informed Targeted Therapy: A Case Report.
Gleason L et al.
International Journal of Dermatology and Venereology, 2023
Case Report: Molecular and microenvironment change upon midostaurin treatment in mast cell leukemia at single-cell level.
Liu MK et al.
Frontiers in Immunology, 2023
c-Kit Receptors as a Therapeutic Target in Cancer: Current Insights.
Abdellateif MS et al.
Oncotargets and Therapy, 2023
Intratumoral heterogeneity of c-KIT mutations in a feline splenic mast cell tumor and their functional effects on cell proliferation.
Hasegawa Y et al.
Scientific Reports, 2022
Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update.
El Hussein S et al.
Cancers, 2022
Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis.
González-López O et al.
Cancers, 2022
Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia.
Katagiri S et al.
International Journal of Molecular Sciences, 2022
Precision Medicine in Systemic Mastocytosis.
Nicolosi M et al.
Medicina (kaunas, Lithuania), 2021
Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders.
Muñoz-González JI et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, 2021
Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis.
Nedoszytko B et al.
International Journal of Molecular Sciences, 2021
Systemic Mastocytosis: Molecular Landscape and Implications for Treatment.
Monaldi C et al.
Mediterranean Journal of Hematology and Infectious Diseases, 2021
Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy.
Martelli M et al.
International Journal of Molecular Sciences, 2020
Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap.
Piris-Villaespesa M et al.
Frontiers in Pharmacology, 2020
Well-differentiated systemic mastocytosis with KIT K509I mutation and uterus infiltration in an Asian woman with good response to imatinib.
Zhao DD et al.
Chinese Medical Journal, 2019
More than the sum of the parts: Toward full-length receptor tyrosine kinase structures.
Diwanji D et al.
Iubmb Life, 2019
Molecular response to imatinib in KIT F522C-mutated systemic mastocytosis.
Broderick V et al.
Leukemia Research, 2019
Computational analysis reveals histotype-dependent molecular profile and actionable mutation effects across cancers.
Heim D et al.
Genome Medicine, 2018
The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.
Roskoski R
Pharmacological Research, 2018
Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature.
Alvarez-Twose I et al.
Oncotarget, 2017
The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.
Jawhar M et al.
Haematologica, 2017
Systemic mastocytosis with KIT V560G mutation presenting as recurrent episodes of vascular collapse: response to disodium cromoglycate and disease outcome.
Conde-Fernandes I et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology, 2017
Targeted Treatment Options in Mastocytosis.
Vaes M et al.
Frontiers in Medicine, 2017
Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report.
Huang L et al.
Medicine, 2016
Targeted ultradeep next-generation sequencing as a method for KIT D816V mutation analysis in mastocytosis.
Kristensen T et al.
European Journal of Haematology, 2016
Clinical and Molecular Diagnostic Evaluation of Systemic Mastocytosis in the South-Eastern Hungarian Population Between 2001-2013--A Single Centre Experience.
Marton I et al.
Pathology Oncology Research : Por, 2016
A scientific treatment approach for acute mast cell leukemia: using a strategy based on next-generation sequencing data.
Youk J et al.
Blood Research, 2016
Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis.
Álvarez-Twose I et al.
The Journal of Allergy and Clinical Immunology, 2016
Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis.
Ke H et al.
Cell & Bioscience, 2016
Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutation.
Kobayashi M et al.
European Journal of Haematology, 2015
Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis.
Gotlib J
Current Hematologic Malignancy Reports, 2015
KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome.
Brahmi M et al.
Bmc Cancer, 2015
Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder.
Chatterjee A et al.
Oncotarget, 2015
Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms.
Pandey R et al.
Molecular Cancer, 2015
KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis.
Arock M et al.
Leukemia, 2015
Evolutionary-guided de novo structure prediction of self-associated transmembrane helical proteins with near-atomic accuracy.
Wang Y et al.
Nature Communications, 2015
The genetic basis of mast cell activation disease - looking through a glass darkly.
Molderings GJ
Critical Reviews in Oncology/hematology, 2015
Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype.
Chan EC et al.
The Journal of Allergy and Clinical Immunology, 2014
Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms.
Cruse G et al.
Immunology and Allergy Clinics of North America, 2014